Effect of MDR1 gene polymorphism on progression of end-stage renal disease

Acta Pharmacologica Sinica

Volumn 28, Issue 4, 2007, Pages 579-583

  Zhang, Wei Xia ^a   Chen, Bing ^a   Zhang, Wen ^a   Chen, Nan ^a   Yu, Zi Cheng ^a   Cai, Wei Min ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

End stage renal disease; Multiple drug resistance gene 1; Polymorphism

Indexed keywords

CREATININE; GLYCOPROTEIN P;

ADULT; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENOTYPE; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL SIGNIFICANCE;

ADULT; ALLELES; CHINA; DISEASE PROGRESSION; DNA; FEMALE; GENE FREQUENCY; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; RISK ASSESSMENT;

EID: 33947614617     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2007.00517.x     Document Type: Article

References (22)

1. Thiebaut F, Tsuruo T, Hamada H, Gottesman M, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735-8.
2. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, et al . Mul tidrug-resistance gene (Pglycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989; 86: 695-8.
3. Motojima M, Nishijima F, Ikoma M, Kawamura T, Yoshioka T, Fogo AB, et al. Role for 'uremic toxin' in the progressive loss of intact nephrons in chronic renal failure. Kidney Int 1991; 40: 461-9.
4. Lysaght MJ, Vonesh EF, Gotch F, Ibels L, Keen M, Lindholm B, et al. The influence of dialysis treatment modality on the decline of remaining renal function. ASAIO Trans 1991; 37: 598-604.
5. Rottembourg J. Residual renal function and recovery of renal function in patients treated by CAPD. Kidney Int 1993; 43: S106-10.
6. Sanaka T, Sugino N, Teraoka S, Ota K. Therapeutic effects of oral sorbent in undialyzed uremia. Am J Kidney Dis 1988; 12: 97-103.
7. Niwa T, Nomura T, Sugiyama S, Miyazaki T, Tsukushi S, Tsutsui S. The protein metabolite hypothesis, a model for the progression of renal failure: An oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int 1997; 52: S23-8.
8. Mickley LA, Lee JS, Weng Z, Zhan Z, Alvarez M, Wilson W, et al. Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood 1998; 91: 1749-56.
9. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrugresistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-8.
10. Siegsmund M, Brinkmann U, Schaffeler E, Weirich G, Schwab M, Eichelbaum M, et al. Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 2002; 13: 1847-54.
11. Roy JN, Barama A, Poirier C, Vinet B, Roger M. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics 2006; 16: 659-65.
12. Woodahl EL, Yang Z, Bui T, Shen DD, Ho RJ. Multidrug resistance gene G1199A polymorphism alters efflux transport activity of P-glycoprotein. J Pharmacol Exp Ther 2004; 310: 1199-207.
13. th ed. Beijing: People's Medical Publishing House.
14. Kroetz DL, Pauli-Magnus C, Hodges LM. Sequence diversity and haplotype structure in the human ABCB1(MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003; 13: 481-94.
15. Zhang WX, Chen GL, Zhang W, Tan ZR, Liu J, Zhou G, et al. MDR1 genotype do not influence the absorption of a single oral dose of 100 mg talinolol in healthy Chinese males. Clin Chim Acta 2005; 359: 46-52.
16. Song P, Lamba JK, Zhang L, Schuetz E, Shukla N, Meibohm B, et al. G2677T and C3435T genotype and haplotype are associated with hepatic ABCB1 (MDR1) expression. J Clin Pharmacol 2006; 46: 373-9.
17. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 2002; 71: 297-303.
18. Kim JH, Shin HD, Park BL, Moon MK, Cho YM, Hwang YH, et al. SLC12A3 (solute carrier family 12 member [sodium/chloride] 3) polymorphisms are associated with end-stage renal disease in diabetic nephropathy. Diabetes 2006; 55: 843-8.
19. Manchanda PK, Kumar A, Bid HK, Mittal RD. Interleukin-1beta and receptor antagonist (IL-1Ra) gene polymorphisms and the prediction of the risk of end-stage renal disease. Biomarkers 2006; 11: 164-73.
20. Lamnissou K, Zirogiannis P, Trygonis S, Demetriou K, Pierides A, Koptides M, et al. Evidence for association of endothelial cell nitric oxide synthase gene polymorphism with earlier progression to end-stage renal disease in a cohort of Hellens from Greece and Cyprus. Genet Test 2004; 8: 319-24.
21. Koupepidou P, Deltas C, Christofides TC, Athanasiou Y, Zouvani I, Pierides A. The MTHFR 677TT and 677CT/1298AC genotypes in Cypriot patients may be predisposing to hypertensive nephrosclerosis and chronic renal failure. Int Angiol 2005; 24: 287-94.
22. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69: 169-74.